眼筋無力症を有する成人参加者におけるロザノロキシズマブの有効性および安全性を評価する研究 (MyVision)
眼筋無力症の成人参加者におけるRozanoloxizumabの有効性および安全性を評価する第3相、無作為化、二重盲検、プラセボ対照試験
The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前：UCB Cares
- 電話番号：+18445992273
- メール：ucbcares@ucb.com
研究連絡先のバックアップ
- 名前：UCB Cares
- 電話番号：00184459922733 (UCB)
- メール：ucbcares@ucb.com
研究場所
-
-
Arizona
-
Scottsdale、Arizona、アメリカ、85251
- 募集
- Mg0038 10104
-
-
Illinois
-
O'Fallon、Illinois、アメリカ、62269
- 募集
- Mg0038 10105
-
-
New York
-
Amherst、New York、アメリカ、14226
- 募集
- Mg0038 10106
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- 募集
- Mg0038 10102
-
Columbus、Ohio、アメリカ、43210
- 募集
- Mg0038 10103
-
-
Wisconsin
-
Greenfield、Wisconsin、アメリカ、53228
- 募集
- Mg0038 10108
-
-
-
-
-
Montreal、カナダ
- 募集
- Mg0038 10201
-
-
-
-
-
Sarajishvili、グルジア
- 募集
- Mg0038 21403
-
Tbilisi、グルジア
- 募集
- Mg0038 21402
-
-
-
-
-
Alicante、スペイン
- 募集
- Mg0038 20605
-
Barcelona、スペイン
- 募集
- Mg0038 20604
-
Barcelona、スペイン
- 募集
- Mg0038 20607
-
Madrid、スペイン
- 募集
- Mg0038 20611
-
Murcia、スペイン
- 募集
- Mg0038 20602
-
Málaga、スペイン
- 募集
- Mg0038 20606
-
Seville、スペイン
- 募集
- Mg0038 20603
-
-
-
-
-
Rüdersdorf、ドイツ
- 募集
- Mg0038 20405
-
-
-
-
-
Dijon、フランス
- 募集
- Mg0038 20303
-
Nantes、フランス
- 募集
- Mg0038 20304
-
Nice、フランス
- 募集
- Mg0038 20301
-
Paris、フランス
- 募集
- Mg0038 20302
-
Paris、フランス
- 募集
- Mg0038 20305
-
-
-
-
-
Katowice、ポーランド
- 募集
- Mg0038 21204
-
Krakow、ポーランド
- 募集
- Mg0038 21203
-
Lublin、ポーランド
- 募集
- Mg0038 21206
-
Warsaw、ポーランド
- 募集
- Mg0038 21202
-
-
-
-
-
Beijing、中国
- 募集
- Mg0038 31901
-
Beijing、中国
- 募集
- Mg0038 31912
-
Beijing、中国
- 募集
- Mg0038 31911
-
Chengdu、中国
- 募集
- Mg0038 31906
-
Chongqing、中国
- 募集
- Mg0038 31908
-
Nanchang、中国
- 募集
- Mg0038 31907
-
Suzhou、中国
- 募集
- Mg0038 31902
-
-
-
-
-
Kobe、日本
- 募集
- Mg0038 31802
-
Minatoku、日本
- 募集
- Mg0038 31804
-
Sendai、日本
- 募集
- Mg0038 31805
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Participant must be a minimum of 18 years of age inclusive at the time of signing the informed consent form (ICF)
-
Participant has Myasthenia Gravis Foundation of America (MGFA) Class I with any ocular weakness at Screening through Baseline. The participant may have weakness in muscles of eye (ie, extraocular muscles that move the eyeball, including the medial rectus, lateral rectus, superior rectus, inferior rectus, superior oblique, and inferior oblique, orbicularis oculi muscles, and levator palpebrae superioris) but must have normal strength in all other facial, bulbar, and limb muscles.
-
Study participant has been diagnosed with Ocular Myasthenia Gravis (oMG) with consistent ocular clinical features at Screening and supported by:
-
Documented presence of autoantibodies against acetylcholine receptor (AChR) or muscle-specific kinase (MuSK), OR
-
Documented absence of autoantibodies against AChR or MuSK; in this case, documented abnormal repetitive nerve stimulation (RNS) or single fiber electromyography (SFEMG) (as defined in the adjudication manual) and at least 1 of the following should be met:
- Documented positive ice test (Ptosis recovers with the ice test [applied 2 minutes (min) to the ptotic lid] with >2mm improvement)
- History of positive edrophonium chloride (Tensilon) test (or equivalent tests used to establish oMG diagnostic as per current practice)
- Demonstrated objective improvement in oMG signs with acetylcholinesterase inhibitor (AChEIs), plasma exchange (PLEX), intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg) or corticosteroids (CSs)
-
Participant has an Myasthenia Gravis Impairment Index (MGII) ocular score (Patient-Reported Outcome (PRO) part) ≥6 with at least 2 ocular items with a score of ≥2 at both Screening and Baseline visits.
-
Participant reported ocular symptom(s) onset <3 years before Screening or ≥3 years provided they have demonstrated response (ie, improvement in ptosis or diploplia) to treatment (IVIg, PLEX, SCIg, pyridostigmine, and/or CSs) in the past year.
-
Participant has no pupillary abnormality except those resulting from prior localized eye disease or surgical intervention.
-
Participant who:
- is currently receiving background treatment for oMG symptoms at the time of Screening and has been receiving treatment for oMG with a stable dose for at least 30 days prior to Screening, OR
- is not receiving any background treatment at the time of Screening
-
Participant has a body weight ≥35kg at Baseline.
Exclusion Criteria:
- Participant has any clinically significant medical or psychiatric condition (including an alcohol or drug use disorder), recent major surgery (including thymectomy [within 3 months of Screening], solid organ, stem cell or marrow transplant), planned major surgery (including thymectomy) during study participation, and/or significant laboratory abnormality that, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study.
- Participant has been diagnosed with other diseases that lead to eyelid dropping, peripheral muscle weakness, or diplopia, including other autoimmune diseases that would interfere with an accurate assessment of the oMG clinical symptoms or other neurological diseases, such as congenital myasthenic syndromes, mitochondrial diseases, and muscular dystrophies.
- Participant has a known hypersensitivity to other anti-Fc receptor (FcRn) medications, to any components of the study medication (including the excipient polysorbate 80) or has a known history of hyperprolinemia, since L-proline is a constituent of the rozanolixizumab formulation.
- Participant has active neoplastic disease or has received treatment for neoplastic disease within 5 years of study entry (except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the uterine cervix, carcinoma in situ of the breast, or incidental histological findings of prostate cancer [Tumor, Node, Metastasis (TNM) stage T1a or T1b] that has been definitely treated with standard of care approaches).
- Participant has a clinically relevant active infection (eg, tuberculosis (TB) infection) or a history of serious infection (resulting in hospitalization or requiring intravenous (iv) antibiotic treatment) within 6 weeks before the Baseline Visit.
- Participant has renal impairment, defined as glomerular filtration rate less than 30milliliter/min/1.73m2 at Screening.
- Participant has been previously treated with FcRn inhibitors.
- Participant has been treated with any of the immunosuppressive medications, biologics, or other therapies, in the specified prohibitive timeframe.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：トリプル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的：Rozanolixizumab
After the Screening Period, participants will enter the study Intervention Period and will be administered study drug for up to 6 weeks. Prior to entering the Intervention Period, study participants will be randomized at a 1:1 ratio and will receive rozanolixizumab. At the End of Treatment Visit, participants will enter an Observation Period of 4 to 7 weeks with an opportunity to transition to an open-label extension study. |
Rozanolixizumab will be administered by subcutaneous infusion.
他の名前：
|
|
プラセボコンパレーター：Placebo
After the Screening Period, participants will enter the study Intervention Period and will be administered study drug for up to 6 weeks. Prior to entering the Intervention Period, study participants will be randomized at a 1:1 ratio and will receive placebo. At the End of Treatment Visit, participants will enter an Observation Period of 4 to 7 weeks with an opportunity to transition to an open-label extension study. |
Placebo will be administered by subcutaneous infusion. |
この研究は何を測定していますか？
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline at Day 43 in (Myasthenia Gravis Impairment Index) MGII ocular score (Patient-Reported Outcome (PRO) part)
時間枠：At Day 43
|
MGII is a measure of disease severity based on the signs and symptoms of MG patients. The MGII has 22 patient-reported items and 6 examination items and scores are presented as a sum of all items for a total score but also as an ocular and generalized sub-score. The scoring range is 0 to 84, 0-23 for the ocular score, and 0-61 for the generalized score, where higher scores are indicative of more severe symptoms. The recall period is "the past week" ie, the last 7 days. |
At Day 43
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline at Day 43 in Myasthenia Gravis Symptoms Patient-Reported Outcome (MGSPRO) ocular muscle weakness scale score
時間枠：At Day 43
|
The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (items 1-5); bulbar muscle weakness (items 6-15); respiratory muscle weakness (items 16-18); physical fatigue (items 19-33) and muscle weakness fatigability (items 34-42). Study participants will be asked to choose response option that best describes how frequently they experienced muscle weakness fatigability (items 34-42) over the past 7 days using a 5-point Likert scale (1="none of the time" to 5="all of the time") for each item. |
At Day 43
|
|
Change from Baseline at Day 43 in Myasthenia Gravis Quality of Life 15-item Scale (revised version) (MG-QoL15r) total score
時間枠：At Day 43
|
The MG-QoL15r is a brief survey, completed by the study participant, that is designed to assess some aspects of "quality of life" related to MG. The recall period that will be used is "past 7 days". When completing the 15-item MG-QoL15r, MG study participant should consider only how their MG affects these items. |
At Day 43
|
|
Change from Baseline at Day 43 in Myasthenia Gravis Activities of Daily Living (MG-ADL) ocular subdomain score
時間枠：At Day 43
|
The total MG-ADL score is obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3). The score ranges from 0 to 24, with a higher score indicating more disability. A positive change indicates worsening and a negative change indicates improvement. |
At Day 43
|
|
Change from Baseline at Day 43 in Myasthenia Gravis Impairment Index (MGII) ocular score (Physical Examination part)
時間枠：At Day 43
|
MGII is a measure of disease severity based on the signs and symptoms of MG patients. The MGII has 22 patient-reported items and 6 examination items and scores are presented as a sum of all items for a total score but also as an ocular and generalized sub-score. The scoring range is 0 to 84, 0-23 for the ocular score, and 0-61 for the generalized score, where higher scores are indicative of more severe symptoms. The recall period is "the past week" ie, the last 7 days. |
At Day 43
|
|
Incidence of treatment-emergent adverse events (TEAEs)
時間枠：Up to Week 13
|
Treatment Emergent Adverse Events (TEAEs) are any untoward medical incidence in a participant after the administration of study treatment, whether or not these events are related to study treatment. |
Up to Week 13
|
|
Incidence of treatment-emergent serious adverse events (TESAEs)
時間枠：Up to Week 13
|
An SAE is defined as any untoward medical occurrence that, at any dose, meets 1 or more of the criteria listed:
|
Up to Week 13
|
|
Incidence of TEAEs leading to permanent withdrawal of study treatment
時間枠：Up to Week 13
|
Treatment Emergent Adverse Events (TEAEs) are any untoward medical incidence in a participant after the administration of study treatment, whether or not these events are related to study treatment. This measure considers any TEAE leading to permanent withdrawal from study. |
Up to Week 13
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- MG0038
- 2025-524756-54-00 (Ctis)
- CTR20262520 (レジストリ識別子：ChinaDrugTrials.org.cn)
- U1111-1334-3276 (その他の識別子：Universal Trial Number)
- 2025 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD 共有時間枠
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD 共有アクセス基準
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。